Palvella Therapeutics PVLA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $2.59M+453% | $468K— | —— | —— | ||
| $22.84M+180% | $8.15M— | —— | —— | ||
| $15.76M+165% | $5.94M— | —— | —— | ||
| $38.6M+174% | $14.1M— | —— | —— | ||
| -$38.6M-174% | -$14.1M— | —— | —— | ||
| —— | $43K— | —— | —— | ||
| -$41.72M-139% | -$17.43M— | —— | —— | ||
| $0— | $0— | —— | —— | ||
| -$41.72M-139% | -$17.43M-193% | $18.69M+156% | -$33.28M+27.2% | ||
| -$3.71+53.3% | -$7.95— | —— | —— | ||
| -$38.6M-174% | -$14.1M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Palvella Therapeutics's revenue?
- Palvella Therapeutics (PVLA) generated $40.9M in revenue over the trailing twelve months, up 142.9% year over year.
- Is Palvella Therapeutics profitable?
- Palvella Therapeutics is not currently profitable: it reported a net loss of $49.3M over the trailing twelve months, a 71.7% net margin.
- What is Palvella Therapeutics's earnings per share?
- Palvella Therapeutics's diluted EPS over the trailing twelve months is $-4.17.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
